Assessment of Protein Modification in Chronic Kidney Disease - Selected Clinical and Biochemical Aspects

Inclusion Criteria

• •The following criteria of qualifying for the study were adopted for all respondents:
• •18 years of age or older,
• •written consent to participate in the study,
• •no smoking for at least 10 years in the history of
• •no alcohol abuse for at least 10 years in a medical history,
• •lack of diabetes and impaired fasting glucose and/or impaired glucose tolerance,
• •no active inflammatory process,
• •no neoplastic disease or a neoplastic disease whose treatment was stopped at least 10 years ago,
• •no history of immunosuppressive treatment,
• •stable liver function (not more than two times increased activity of transaminases), HBs antigen and anti-HCV negative antibodies,
• •anti-HIV negative antibodies.
• •In addition, for CKD patients, the following additional inclusion conditions were applied:
• •no additional comorbidities that do not result directly or indirectly from CKD,
• •no acute cardiovascular complications, ie acute heart failure, hypertensive crisis, acute coronary syndrome, at the time of study entry.
• •in group HD:
• •a minimum of 6 months of treatment with repeated hemodialysis, 3 times a week, for a minimum of 10 hours a week,
• •arteriovenous fistula as a vascular access for hemodialysis,
• •Estimated dialysis adequacy ratio (eKt / V) of at least 1.2. in the PD group:
• •treatment duration UP to a minimum of 6 months,
• •Kt / V ≥1.8 l / week / 1.73 m2.
• •For CARD patients, additional conditions include:
• •no obvious evidence of renal impairment in the history and at the time of study entry, renal function assessed on the basis of eGFR and urine albumin/creatinine ratio,
• •history of angina,
• •documented history of at least one acute coronary syndrome,
• •admission to the Department of Intensive Care of Cardiology and Internal Diseases in order to perform a planned coronary angiography,
• •on the day of admission to the study without signs of acute coronary syndrome,
• •no additional comorbidities, ie those that do not result directly or indirectly from coronary heart disease.
• •In turn, for the HV group, additional conditions include:
• •no obvious evidence of renal impairment in the history and at the time of study entry, renal function assessed on the basis of eGFR and urine albumin/creatinine ratio,
• •no obvious signs of cardiovascular impairment in the history and at the time of study entry, estimated on the basis of normal blood pressure (\<140/90 mmHg), no abnormalities in the medical history and physical examination,
• •not taking any medications on a regular basis.